Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma宣佈12個月最新進展情況，包括股東信函
Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
開拓自身免疫性疾病細胞療法的臨床階段生物製藥公司Immix Biopharma, Inc.（納斯達克股票代碼：IMMX）今天宣佈了包括股東信函在內的12個月最新進展。
"The past 12 months have seen landmark achievements for Immix Biopharma, cementing our position as a leading cell therapy company in autoimmune disease. We successfully received U.S. FDA investigational new drug clearance for NXC-201. NXC-201 is the only CAR-T in AL Amyloidosis and is expanding into additional autoimmune indications, a $25 billion combined annual market segment, where limited treatments are available today. At the 65th American Society of Hematology (ASH) annual meeting in December 2023, we presented...
“在過去的12個月中，Immix Biopharma取得了里程碑式的成就，鞏固了我們作爲自身免疫性疾病領域領先細胞療法公司的地位。我們成功獲得美國食品...
登入免費觀看全文
登入/註冊